All In Biotech

Drug Trial Radar · NCT00809354

Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip

A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY OF THE LONG-TERM ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB ALONE OR IN COMBINATION WITH NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) VERSUS NSAIDS ALONE IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE OR HIP

Last checked: Nov 19, 2026Latest source record: Jun 24, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,720 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

2,720

Actual

Start

Feb 12, 2009

Primary completion

Oct 28, 2010

Study completion Jan 12, 2011

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Dec 17, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to investigate the long-term analgesic efficacy and safety of tanezumab for patients with osteoarthritis (OA) of the knee or hip currently experiencing partial benefit from, and are tolerating, non-steroidal anti-inflammatory drug (NSAID) therapy.

Conditions

  • Osteoarthritis
  • Arthritis

Interventions

  • NSAIDDrug

    IV doses of placebo (to match tanezumab) every 8 weeks (through Week 48) plus oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks

  • tanezumabBiological

    IV tanezumab 5 mg every 8 weeks (through Week 48) and oral placebo for NSAID BID from Weeks 2 through 56

  • tanezumabBiological

    IV tanezumab 10 mg every 8 weeks (through Week 56) and oral placebo for NSAID BID from Weeks 2 through 56

  • tanezumabBiological

    IV tanezumab 5 mg every 8 weeks (through Week 48)

  • NSAIDDrug

    Oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks

  • tanezumabBiological

    IV tanezumab 10 mg every 8 weeks (through Week 48)

  • NSAIDDrug

    Oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Week 16Time frame: Baseline, Week 16
  2. Change From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Score at Week 16Time frame: Baseline, Week 16
  3. Change From Baseline in the Patient Global Assessment (PGA) of Osteoarthritis at Week 16Time frame: Baseline, Week 16

Locations

333 sites in 12 countries. Site status is shown where the registry gives one.

  • Rheumatology Associates, P.C.

    Birmingham, Alabama

  • Radiant Research

    Birmingham, Alabama

  • Alliance Clinical Research

    Birmingham, Alabama

  • Shades Mountain Imaging

    Birmingham, Alabama

  • Rheumatology Associates of North Alabama, PC

    Huntsville, Alabama

  • Saadat Ansari, MD Office

    Huntsville, Alabama

  • Coastal Clinical Research, Inc.

    Mobile, Alabama

  • Office of Vaughn H. Mancha, Jr., MD

    Montgomery, Alabama

  • Radiant Research - Phoenix Southeast

    Chandler, Arizona

  • Dedicated Clinical Research

    Goodyear, Arizona

  • Eclipse Clinical Research

    Green Valley, Arizona

  • Midwest Internal Medicine, PLLC

    Lake Havasu City, Arizona

  • Arizona Arthritis & Rheumatology Associates, P.C.

    Mesa, Arizona

  • Pivotal Research Centers

    Mesa, Arizona

  • Arizona Arthritis & Rheumatology Research, PLLC

    Paradise Valley, Arizona

  • Pivotal Research Centers

    Peoria, Arizona

  • Elite Clinical Studies, LLC

    Phoenix, Arizona

  • Arizona Arthritis & Rheumatology Associates, P.C.

    Phoenix, Arizona

  • Cochise Clinical Research

    Sierra Vista, Arizona

  • Premiere Phamaceutical Research, LLC

    Tempe, Arizona

  • Radiant Research

    Tucson, Arizona

  • Arizona Research Associates

    Tucson, Arizona

  • Quality of Life Medical and Research Center

    Tucson, Arizona

  • Tucson Orthopaedic Institute

    Tucson, Arizona

  • Little Rock Diagnostic Clinic, PA

    Little Rock, Arkansas

  • Little Rock Family Practice Clinic

    Little Rock, Arkansas

  • Advanced Clinical Research Institute

    Anaheim, California

  • Orange County Clinical Trials, Inc.

    Anaheim, California

  • Med Center

    Carmichael, California

  • eStudySite

    Chula Vista, California

  • Med Investigations, Inc.

    Fair Oaks, California

  • Triwest Research

    La Mesa, California

  • Lakewood Orthopedic Medical & Surgical Group

    Lakewood, California

  • Premier Clinical Research LLC.

    Lakewood, California

  • Prohealth Partners

    Long Beach, California

  • Peak Health Medical Group, Inc.

    Los Angeles, California

  • Synergy Clinical Research Center

    National City, California

  • eStudySite

    Oceanside, California

  • Desert Medical Group Inc., Desert Oasis Healthcare

    Palm Springs, California

  • Advances in Medicine

    Rancho Mirage, California

Showing 40 of 333 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.